Literature DB >> 14600576

Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection.

Kathleen M Neuzil1, Christopher S Coffey, Ed F Mitchel, Marie R Griffin.   

Abstract

The etiologic role of influenza in hospitalizations and deaths among persons infected with HIV since the introduction of highly active antiretroviral therapy (HAART) is not known. A retrospective cohort study was performed of all persons aged 15 to 50 years with AIDS or advanced HIV infection enrolled in the Tennessee Medicaid program from 1995 through 1999, representing 7368 person-years of follow-up. The influenza season was defined based on local virus surveillance, and hospitalizations were measured for acute cardiopulmonary causes and deaths from any cause throughout the year. From 1995 through 1999, cardiopulmonary hospitalization rates in HIV-infected patients declined by 53% and death rates declined by 77%. The influenza-attributable hospitalization rate was 48 (95% confidence interval [CI]: 16-91) per 1000 persons in 1995 and 5 (95% CI: -0.5-11) per 1000 persons per year during 1996 through 1999, after the introduction of HAART. Influenza-associated hospitalizations have declined in patients with HIV infection in the post-HAART era. Rates remain comparable to rates in other high-risk groups for which annual influenza vaccination is recommended, however.

Entities:  

Mesh:

Year:  2003        PMID: 14600576     DOI: 10.1097/00126334-200311010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  25 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.

Authors:  Hana M El Sahly; Charles Davis; Karen Kotloff; Jeffery Meier; Patricia L Winokur; Anna Wald; Christine Johnston; Sarah L George; Rebecca C Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A Keitel
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

Review 3.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature.

Authors:  Anandi N Sheth; Keri N Althoff; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 4.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

Review 5.  Immunization of HIV-infected adult patients - French recommendations.

Authors:  Anne Frésard; Amandine Gagneux-Brunon; Frédéric Lucht; Elisabeth Botelho-Nevers; Odile Launay
Journal:  Hum Vaccin Immunother       Date:  2016-07-13       Impact factor: 3.452

6.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

7.  Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.

Authors:  Yu Bin Seo; Jacob Lee; Joon Young Song; Hee Jung Choi; Hee Jin Cheong; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

8.  Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells.

Authors:  Lorenzo A Ramirez; Alexander Daniel; Ian Frank; Pablo Tebas; Jean D Boyer
Journal:  J Infect Dis       Date:  2014-03-08       Impact factor: 5.226

9.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

10.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children.

Authors:  Myron J Levin; Lin-Ye Song; Terrence Fenton; Sharon Nachman; Julie Patterson; Robert Walker; George Kemble; Maria Allende; Micki Hultquist; Tingting Yi; Barbara Nowak; Adriana Weinberg
Journal:  Vaccine       Date:  2008-06-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.